Samantha Shenoy, NP, MSN, provides nursing guidance on teclistamab/subcutaneous daratumumab’s second-line approval in multiple myeloma. On March 5, the FDA approved the combination of teclistamab ...
Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients living with ocular MG ...
Accelerated review was enabled by the Commissioner’s National Priority Voucher Pilot Program, targeting high unmet need and ...
This report describes a female patient in her 60s with an immune-mediated necrotising myopathy (IMNM) occurring after ...
The FDA approved Darzalex Faspro with Velcade, Revlimid and dexamethasone for newly diagnosed multiple myeloma ineligible for autologous stem cell transplant. The U.S. Food and Drug Administration ...
Treatment for chronic inflammatory demyelinating polyneuropathy (CIDP), a chronic autoimmune condition that affects the protective layer around your nerves, usually starts with one of three options.
A Prescription Drug User Fee Act target date of May 24, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License ...
With star checkpoint inhibitors like Keytruda and Opdivo now sporting subcutaneous formulations, GSK has struck a deal aimed at ensuring its own PD-1 stalwart doesn’t miss out on the action. GSK, ...
Subcutaneous (SC) formulations of monoclonal antibodies are rapidly transforming the delivery of cancer immunotherapy. Designed to replace or complement intravenous (IV) administration, SC delivery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results